Withhold Trastuzumab in Low-Risk Patients with HER-2 Positive Breast Cancer?
REFERENCE: Abstract: 2090
RACHEL JOHNSON, Christie Hospital, Manchester
Some patients with HER-2 positive early breast cancer fare better if trastuzumab is withheld, according to the findings of a 1,000 patient study looking at the additional toxicity of adjuvant trastuzumab when combined with chemotherapy according to the current guidelines. In San Antonio, Rachel Johnson discussed the balance of risks among patients with node-negative mammographically detected breast cancer.
Early Breast Cancer: Exemestane Therapy Benefits After Five Years of Tamoxifen
REFERENCE: Abstract 49
TERRY MAMOUNAS, Aultman Cancer Center, Canton OH
The use of the aromatase inhibitor exemestane after five years of tamoxifen therapy in postmenopausal patients with early breast cancer brought further benefits. Terry Mamounas told Peter Goodwin about his group’s results from the National Surgical Adjuvant Breast and Bowel Project B-33, which he presented in San Antonio.
Fulvestrant Or Exemestane When Aromatase Inhibition Fails Initially?
REFERENCE: SABCS 2006 Abstract: 12
WILLIAM GRADISHAR, Northwestern University, Chicago
Both fulvestrant and exemestane were found to be equally effective for treating patients with advanced breast cancer, after disease progression following initial aromatase inhibitor therapy. William Gradishar discussed the findings of the EFFECT trial with Karen Regester.
To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.